Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...

The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...

IgA nephropathy (IgAN) is characterized by the deposition of IgA1-containing immune complexes in the glomerular mesangium. The pathogenesis follows a 4-hit cascade: ...

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

Why Do I Have IgA Nephropathy? Even though it’s one of the most common kidney diseases, doctors don’t know why it happens. It most often appears in adolescence or younger adulthood.

IgA nephropathy is progressive. That means it gets worse the longer you have it. It's not curable, but treatments can slow kidney damage and keep these organs working longer. It's important to ...

An increase in the proportion of serum IgA molecules that are poorly O-galactosylated has been one of the most consistent findings in studies of IgAN over the past decade. 1,2 Perhaps more ...

Andrew S. Bomback, MD, MPH, comments on the impact of disparities in diagnosing and treating IgA nephropathy by nephrologists. Early detection and treatment of IgA nephropathy are critical for ...

Fibroblast activating protein inhibitor (FAPI) PET/CT imaging may be a non-invasive modality to monitor IgA nephropathy (IgAN) progression, preliminary study results suggest.